18F-AV-133 ( DrugBank: 18F-AV-133 )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
6パーキンソン病3

6. パーキンソン病


臨床試験数 : 2,298 薬物数 : 2,202 - (DrugBank : 350) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 202
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR2000036137
2020-10-012020-08-21Clinical study of 18F-FDG combined with 18F-AV-133 PET/CT imaging in the diagnosis and differentiation of primary Parkinson's diseaseClinical study of 18F-FDG combined with 18F-AV-133 PET/CT imaging in the diagnosis and differentiation of primary Parkinson's disease Parkinson’s diseaseGold Standard:UK Parkinson's disease Society Brain Bank Clinical Diagnosis Criteria;Index test:18F-FDG combined with 18F-AV-133 PET/CT imaging;Renji Hospital (South Court), School of Medicine, Shanghai Jiao Tong UniversityNULLPendingBothTarget condition:50;Difficult condition:0China
2NCT01550484
(ClinicalTrials.gov)
April 20126/3/2012A Trial of 18F-AV-133 Positron Emission Tomography (PET) Imaging to Differentiate Subjects With Parkinson's Disease (PD) From Other Movement DisordersAn Open Label, Multicenter Study, Evaluating the Safety and Efficacy of 18F-AV-133 PET Imaging to Identify Subjects With Dopaminergic Degeneration Among Subjects Presenting to a Movement Disorders Specialty Clinic With an Uncertain DiagnosisParkinson's Disease;Primary Parkinsonism;Lewy Body Parkinson's DiseaseDrug: 18F-AV-133Avid RadiopharmaceuticalsNULLCompleted40 YearsN/AAll170Phase 2/Phase 3United States;Australia
3NCT01503944
(ClinicalTrials.gov)
March 201014/7/2010A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET)Detection of Striatal Dopaminergic Degeneration and Neocortical Amyloid Pathology in Patients With Dementia With Lewy Bodies, Alzheimer's Disease, Parkinson's Disease, and Healthy Elderly VolunteersDementia With Lewy Bodies;Alzheimer's Disease;Parkinson's DiseaseDrug: 18F-AV-133;Drug: 18F-AV-45Avid RadiopharmaceuticalsNULLCompleted50 YearsN/ABoth30Phase 1/Phase 2United States